Literature DB >> 21180546

Tailoring the treatment to the individual in Crohn's disease.

Edouard Louis1, Jacques Belaiche, Catherine Reenaers.   

Abstract

Crohn's disease is a heterogeneous disease with approximately 30-40% of patients having a simple benign history and the rest having a chronic progressive disease leading to complications, surgeries and potentially socio-professional marginalisation. Recent studies have shown that an early treatment with immunosuppressive treatment and/or anti-tumour necrosis factor agents could change the natural history of the disease and avoid the development of such disabling disease. The therapy should thus be tailored according to the risk of developing such disabling disease. Recent cohort studies have shown that clinical factors such as age at diagnosis, disease extent, disease location and behaviour at diagnosis were predictive for the development of severe or disabling disease and could be used in helping the physician to tailor therapy.

Entities:  

Keywords:  Crohn's disease; tailored therapy; tumour necrosis disease

Year:  2009        PMID: 21180546      PMCID: PMC3002523          DOI: 10.1177/1756283X09337180

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  24 in total

1.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.

Authors:  Gary R Lichtenstein; Songkai Yan; Mohan Bala; Marion Blank; Bruce E Sands
Journal:  Gastroenterology       Date:  2005-04       Impact factor: 22.682

2.  Predictors of severe Crohn's disease.

Authors:  Catherine Loly; Jacques Belaiche; Edouard Louis
Journal:  Scand J Gastroenterol       Date:  2008-08       Impact factor: 2.423

3.  Phenotype at diagnosis predicts recurrence rates in Crohn's disease.

Authors:  F L Wolters; M G Russel; J Sijbrandij; T Ambergen; S Odes; L Riis; E Langholz; P Politi; A Qasim; I Koutroubakis; E Tsianos; S Vermeire; J Freitas; G van Zeijl; O Hoie; T Bernklev; M Beltrami; D Rodriguez; R W Stockbrügger; B Moum
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

4.  Unemployment and disability in patients with moderately to severely active Crohn's disease.

Authors:  Brian G Feagan; Mohan Bala; Songkai Yan; Allan Olson; Stephen Hanauer
Journal:  J Clin Gastroenterol       Date:  2005 May-Jun       Impact factor: 3.062

5.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

6.  National Cooperative Crohn's Disease Study: factors determining recurrence of Crohn's disease after surgery.

Authors:  H S Mekhjian; D M Switz; H D Watts; J J Deren; R M Katon; F M Beman
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

7.  Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy.

Authors:  Matthieu Allez; Marc Lemann; Joëlle Bonnet; Pierre Cattan; Raymond Jian; Robert Modigliani
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

8.  Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery.

Authors:  J Cosnes; I Nion-Larmurier; L Beaugerie; P Afchain; E Tiret; J-P Gendre
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

9.  Disability from inflammatory bowel disease among employees in West Germany.

Authors:  A Sonnenberg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

10.  Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes.

Authors:  Steven R Brant; Michael F Picco; Jean-Paul Achkar; Theodore M Bayless; Sunanda V Kane; Aaron Brzezinski; Franklin J Nouvet; Denise Bonen; Amir Karban; Themistocles Dassopoulos; Reda Karaliukas; Terri H Beaty; Stephen B Hanauer; Richard H Duerr; Judy H Cho
Journal:  Inflamm Bowel Dis       Date:  2003-09       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.